Bicycle Therapeutics plc
NASDAQ:BCYCBiotechnology
-$0.06 today
- Market cap
- $217.99M
- Beta
- 1.54
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$3.14
Volume 0.57M
Average 0.49M
BCYC Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Bicycle Therapeutics plcNASDAQ: BCYC
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $1.13M fell 31.2% year over year, behind the -17.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 15.5% from the prior quarter. Over 3 fiscal years it compounded at +20.3% a year.
Context
- Depreciation & amortization amounted to 8.8% of revenue in FY2025, down 11.5 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -31.2% toward the trailing-twelve-month pace of -17.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 6.42M USD
- Year-over-year change
- -10.5%
- 4-year CAGR
- +46.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.42M | -10.5% |
| FY2024 | 2024-12-31 | 7.18M | +9.6% |
| FY2023 | 2023-12-31 | 6.55M | +77.4% |
| FY2022 | 2022-12-31 | 3.69M | +161.8% |
| FY2021 | 2021-12-31 | 1.41M | — |
Depreciation & Amortization vs competitors
How BCYC compares with its peers on the latest reported figures
- BCYC's LTM Mar 2026 depreciation & amortization of $5.92M is the 2nd highest of the 10 companies compared; the peer median is $1.19M.
- Its year-over-year change of -17.6% is the 6th highest of 9, against a peer median of -9.0%.
- Depreciation & amortization amounts to 9.3% of revenue for BCYC, versus a peer median of 2.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.46M | +0.4% | +46.9% | 7.3% | |
| LTM Mar 2026 | $5.92M | -17.6% | +20.3% | 9.3% | |
| LTM Mar 2026 | $2.31M | +156.8% | +70.7% | 4.0% | |
| LTM Dec 2025 | $1.56M | — | — | 1.3% | |
| LTM Mar 2026 | $1.38M | -6.3% | -16.8% | — | |
| LTM Mar 2026 | $1.19M | -63.3% | -7.7% | 1.5% | |
| LTM Mar 2026 | $1.12M | -32.0% | -8.2% | — | |
| LTM Mar 2026 | $914K | -11.7% | +0.4% | 9.2% | |
| LTM Mar 2026 | $555K | -1.9% | +13.3% | 0.8% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59K | -90.6% | -29.5% | — |
| Peer median (excluding BCYC) | $1.19M | -9.0% | -3.7% | 2.7% | |
Competitors are the stored peer set for BCYC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 11.7M | 14.46M | 26.98M | 35.28M | 72.59M |
| Cost of Revenue | 0 | 0 | 156.5M | 172.97M | 0 |
| Gross Profit | 11.7M | 14.46M | (129.52M) | (137.69M) | 72.59M |
| Gross Margin | 100.0% | 100.0% | -480.1% | -390.3% | 100.0% |
| Research & Development | 44.88M | 81.61M | 156.5M | 172.97M | 240.28M |
| Selling, General & Admin | 32.44M | 49.51M | 59.83M | 71.46M | 80.02M |
| Operating Expenses | 77.32M | 131.12M | 60.43M | 72.18M | 320.3M |
| Depreciation & Amortization | 1.41M | 3.69M | 6.55M | 7.18M | 6.42M |
| EBITDA | (64.09M) | (107.21M) | (169.4M) | (164.89M) | (212.18M) |
| EBITDA Margin | -547.9% | -741.3% | -628.0% | -467.4% | -292.3% |
| Operating Income | (65.62M) | (116.65M) | (189.95M) | (209.87M) | (247.72M) |
| Operating Margin | -561.0% | -806.6% | -704.1% | -595.0% | -341.3% |
| Interest Income | 120K | 5.76M | 14M | 34.28M | 28.46M |
| Interest Expense | 2.98M | 3.34M | 3.26M | 1.73M | 206K |
| Other Income / Expenses | (2.86M) | 2.41M | 10.74M | 36.08M | 28.91M |
| Income Before Tax | (68.48M) | (114.24M) | (179.21M) | (173.8M) | (218.81M) |
| Pre-Tax Margin | -585.5% | -789.9% | -664.3% | -492.7% | -301.4% |
| Income Tax Expense | (1.66M) | (1.52M) | 1.46M | (4.77M) | 152K |
| Net Income | (66.82M) | (112.72M) | (180.66M) | (169.03M) | (218.96M) |
| Net Margin | -571.2% | -779.3% | -669.7% | -479.2% | -301.7% |
| EPS (Basic) | (2.67) | (3.80) | (5.08) | (2.91) | (3.16) |
| EPS (Diluted) | (2.67) | (3.80) | (5.08) | (2.90) | (3.16) |
| Weighted Avg Shares | 25.06M | 29.66M | 35.59M | 58.21M | 69.28M |
| Weighted Avg Shares (Diluted) | 25.06M | 29.66M | 35.59M | 58.21M | 69.28M |
Bicycle Therapeutics plc
NASDAQ:BCYC
Intrinsic Alpha fair value
Locked
Current Price
$3.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.